Compare FET & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FET | ABEO |
|---|---|---|
| Founded | 2005 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.5M | 281.0M |
| IPO Year | 2012 | 1980 |
| Metric | FET | ABEO |
|---|---|---|
| Price | $39.14 | $5.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.20 |
| AVG Volume (30 Days) | 132.8K | ★ 1.2M |
| Earning Date | 02-19-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | ★ $790,292,000.00 | $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.75 | $1,589.77 |
| P/E Ratio | ★ N/A | $4.05 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.78 | $3.93 |
| 52 Week High | $39.85 | $7.54 |
| Indicator | FET | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 69.12 | 50.82 |
| Support Level | $35.70 | $5.11 |
| Resistance Level | $39.85 | $5.40 |
| Average True Range (ATR) | 1.86 | 0.22 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 91.05 | 49.33 |
Forum Energy Technologies Inc is a products company, serving the oil, natural gas, industrial and renewable energy industries. The company designs, manufactures, and distributes products and engages in aftermarket parts supply and services that complement its product offering. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. It operates in two reporting segments, namely Drilling and Completions and Artificial Lift and Downhole. Revenue largely comes from Artificial Lift and Downhole segment.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.